首页 | 本学科首页   官方微博 | 高级检索  
     


A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor,in patients with advanced solid tumors
Authors:Alex A. Adjei  Patricia LoRusso  Antoni Ribas  Jeffrey A. Sosman  Anna Pavlick  Grace K. Dy  Xiaofei Zhou  Esha Gangolli  Michelle Kneissl  Stephanie Faucette  Rachel Neuwirth  Viviana Bózon
Affiliation:1.Department of Oncology,Mayo Clinic,Rochester,USA;2.Yale University,New Haven,USA;3.University of California at Los Angeles Jonsson Comprehensive Cancer Center,Los Angeles,USA;4.Vanderbilt-Ingram Cancer Center,Nashville,USA;5.New York University Langone Medical Center,New York,USA;6.Roswell Park Cancer Institute,Buffalo,USA;7.Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited,Cambridge,USA;8.AstraZeneca Pharmaceuticals,Waltham,USA;9.Present address: Array BioPharma Inc.,Boulder,USA
Abstract:
Keywords:
本文献已被 SpringerLink 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号